The Pulse Check

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Jul 6, 2026

•

5 min read

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Jason Segal

Optiscan (ASX: OIL)

Margin Call: The Optiscan Story (ASX: OIL)

Jul 2, 2026

•

12 min read

Margin Call: The Optiscan Story (ASX: OIL)

Jason Segal

The Pulse Check

A Deep Dive into Brain-Computer Interfaces: The US$400 Billion Industry

Jul 1, 2026

•

7 min read

A Deep Dive into Brain-Computer Interfaces: The US$400 Billion Industry

Jason Segal

The Pulse Check

A Closer Look at the ASX Supervision Report

Jun 30, 2026

•

6 min read

A Closer Look at the ASX Supervision Report

Jason Segal

Emyria (ASX: EMD)

Acid Test: Definium’s Positive Phase 3 LSD Readout

Jun 29, 2026

•

4 min read

Acid Test: Definium’s Positive Phase 3 LSD Readout

Jason Segal

The Pulse Check

Jun 26, 2026

•

3 min read

Is Medtech Back?

Jason Segal

The Pulse Check

My Third Armchair Pick: Control Bionics (ASX: CBL)

Jun 25, 2026

•

13 min read

My Third Armchair Pick: Control Bionics (ASX: CBL)

Jason Segal

The Pulse Check

Avecho’s (AVE) Phase 3 Insomnia Result Awakens Biotech Market

Jun 24, 2026

•

4 min read

Avecho’s (AVE) Phase 3 Insomnia Result Awakens Biotech Market

Jason Segal

The Pulse Check

Jun 23, 2026

•

9 min read

Fighting over the shrinking pie

Jason Segal

The Pulse Check

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Jun 22, 2026

•

9 min read

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Jason Segal

The Pulse Check

Tax On, Tax Off: What new changes mean for biotech

Jun 19, 2026

•

4 min read

Tax On, Tax Off: What new changes mean for biotech

Jason Segal

The Pulse Check

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Jun 18, 2026

•

4 min read

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Jason Segal

Emyria (ASX: EMD)

Jun 17, 2026

•

4 min read

Fireside Conversation with Emyria

Jason Segal

The Pulse Check

Catalyst Hunting: The Actinogen Story (ASX: ACW)

Jun 16, 2026

•

10 min read

Catalyst Hunting: The Actinogen Story (ASX: ACW)

Jason Segal

The Pulse Check

The Hardest Sport in Business: Attention

Jun 15, 2026

•

3 min read

The Hardest Sport in Business: Attention

Jason Segal

The Pulse Check

A Sweaty Mess: The Botanix Story (ASX: BOT)

Jun 12, 2026

•

8 min read

A Sweaty Mess: The Botanix Story (ASX: BOT)

Jason Segal

The Pulse Check

The Competitive Landscape of the Healthcare World Cup

Jun 11, 2026

•

6 min read

The Competitive Landscape of the Healthcare World Cup

Jason Segal

Imricor (ASX: IMR)

Big Game Hunting: The Imricor Story (ASX: IMR)

Jun 10, 2026

•

11 min read

Big Game Hunting: The Imricor Story (ASX: IMR)

Jason Segal

The Pulse Check

Jun 9, 2026

•

4 min read

The Big Freeze: Neale’s legacy lives on

Jason Segal

The Pulse Check

Opthea Trade Update: The Final Boss Levelled Up

Jun 5, 2026

•

3 min read

Opthea Trade Update: The Final Boss Levelled Up

Jason Segal

The Pulse Check

Jun 4, 2026

•

7 min read

5 Tax Loss Trading Stocks I’m Watching

Jason Segal

The Pulse Check

Opthea (ASX: OPT) is back: Can you SEE the trade?

Jun 3, 2026

•

2 min read

Opthea (ASX: OPT) is back: Can you SEE the trade?

Jason Segal

The Pulse Check

Shelf Control: The Cryosite Story (ASX: CTE)

Jun 2, 2026

•

10 min read

Shelf Control: The Cryosite Story (ASX: CTE)

Jason Segal

The Pulse Check

Two new contracts put Pro Medicus back in focus

Jun 1, 2026

•

4 min read

Two new contracts put Pro Medicus back in focus

Jason Segal

The Pulse Check

May 29, 2026

•

2 min read

Six months in the chair. Thank you!

Jason Segal

The Pulse Check

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Margin Call: The Optiscan Story (ASX: OIL)

A Deep Dive into Brain-Computer Interfaces: The US$400 Billion Industry

A Closer Look at the ASX Supervision Report

Acid Test: Definium’s Positive Phase 3 LSD Readout

Is Medtech Back?

My Third Armchair Pick: Control Bionics (ASX: CBL)

Avecho’s (AVE) Phase 3 Insomnia Result Awakens Biotech Market

Fighting over the shrinking pie

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Tax On, Tax Off: What new changes mean for biotech

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Fireside Conversation with Emyria

Catalyst Hunting: The Actinogen Story (ASX: ACW)

The Hardest Sport in Business: Attention

A Sweaty Mess: The Botanix Story (ASX: BOT)

The Competitive Landscape of the Healthcare World Cup

Big Game Hunting: The Imricor Story (ASX: IMR)

The Big Freeze: Neale’s legacy lives on

Opthea Trade Update: The Final Boss Levelled Up

5 Tax Loss Trading Stocks I’m Watching

Opthea (ASX: OPT) is back: Can you SEE the trade?

Shelf Control: The Cryosite Story (ASX: CTE)

Two new contracts put Pro Medicus back in focus

Six months in the chair. Thank you!

The Armchair Analyst